Diagnostic and prognostic value of serum MACC1 in breast cancer patients
PDF | HTML | How to cite
Metrics: PDF 1623 views | HTML 1791 views | ?
Weige Tan1,5, Xinhua Xie2,3,5, Laisheng Li4,5, Hailin Tang2,3, Xigang Ye1, Lun Chen1, Wei Tang1, Jin Gao1, Lingxiao Pan1, Xiaoshen Zhang1, Feng Ye2,3, Xing Li2,3, Lu Yang2,3, Xiaoming Xie2,3, Wenbo Zheng1
1Department of Breast Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China
2Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China
3Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China
4Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China
5These authors contributed equally to this work
Wenbo Zheng, email: [email protected]
Xiaoming Xie, email: [email protected]
Keywords: MACC1, breast cancer, diagnosis, biomarker, serum
Received: September 07, 2016 Accepted: October 14, 2016 Published: October 25, 2016
Metastasis-associated in colon cancer-1 (MACC1) promotes colorectal cancer progression and predicts prognosis. The aim of our study was to determine the diagnostic and prognostic value of preoperative serum MACC1 levels in breast cancer patients. Serum MACC1 levels were measured in 378 breast cancer patients, 120 patients with benign breast disease, and 40 healthy volunteers using an ELISA. Serum MACC1 levels were higher in breast cancer patients than patients with benign disease or healthy volunteers. Increased serum MACC1 was associated with breast cancer TNM stage (P < 0.001), tumor size (P < 0.001), lymph node metastasis (P < 0.001), and Ki-67 status (P = 0.014). Serum MACC1 measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.785, 95% CI: 0.746–0.825) with an optimal cut-off value of 38.35 pg/ml (sensitivity = 0.725, specificity = 0.696). Moreover, serum MACC1 exhibited significant prognostic value in breast cancer (AUC = 0.757, 95% CI: 0.700–0.814), and high MACC1 was associated with poor disease-free survival (HR 5.63, 95% CI: 3.51–9.04; P < 0.001). Our findings demonstrated that circulating MACC1 could serve as a reliable diagnostic and prognostic biomarker for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.